Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Br J Cancer ; 91(8): 1488-94, 2004 Oct 18.
Article in English | MEDLINE | ID: mdl-15381928

ABSTRACT

Small peptides that perturb intracellular signalling pathways are useful tools in the identification and validation of new drug targets. To facilitate the analysis of biologically active peptides, we have developed retroviral vectors expressing an intracellular scaffold protein that significantly enhances the stability of small peptides in mammalian cells. This approach was chosen because retroviral transduction results in efficient and controlled delivery of the gene encoding the effector peptide, while the scaffold protein not only stabilises the peptide but also facilitates the analysis and potential isolation of the target protein. Here, we have adapted a p53-responsive reporter assay to flow cytometry to demonstrate the versatility of this approach by using peptides with known Mdm2-binding activities inserted into a stable scaffold protein that is suitable for intracellular expression in multiple compartments of mammalian cells. This strategy should be generally applicable to the study of small biologically active peptides in diverse functional assays.


Subject(s)
Bone Neoplasms/metabolism , Genetic Vectors/genetics , Nuclear Proteins/metabolism , Osteosarcoma/metabolism , Peptide Fragments/metabolism , Proto-Oncogene Proteins/metabolism , Receptors, Growth Factor , Retroviridae/genetics , Tumor Suppressor Protein p53/metabolism , Bone Neoplasms/pathology , Carrier Proteins/genetics , Carrier Proteins/metabolism , Humans , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Nuclear Proteins/genetics , Osteosarcoma/pathology , Peptide Fragments/genetics , Protein Binding , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-mdm2 , Receptors, Nerve Growth Factor , Transfection , Tumor Cells, Cultured/metabolism , Tumor Suppressor Protein p14ARF/genetics , Tumor Suppressor Protein p14ARF/metabolism , Tumor Suppressor Protein p53/genetics , beta-Galactosidase/genetics , beta-Galactosidase/metabolism
2.
J Virol ; 73(10): 8873-9, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10482646

ABSTRACT

In vivo passage of a simian-human immunodeficiency virus (SHIV-89.6) generated a virus, SHIV-89.6P, that exhibited increased resistance to some neutralizing antibodies (G. B. Karlsson et al., J. Exp. Med. 188:1159-1171, 1998). Here we examine the range of human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies to which the passaged virus became resistant and identify envelope glycoprotein determinants of antibody resistance. Compared with the envelope glycoproteins derived from the parental SHIV-89.6, the envelope glycoproteins of the passaged virus were resistant to antibodies directed against the gp120 V3 variable loop and the CD4 binding site. By contrast, both viral envelope glycoproteins were equally sensitive to neutralization by two antibodies, 2G12 and 2F5, that recognize poorly immunogenic structures on gp120 and gp41, respectively. Changes in the V2 and V3 variable loops of gp120 were necessary and sufficient for full resistance to the IgG1b12 antibody, which is directed against the CD4 binding site. Changes in the V3 loop specified complete resistance to a V3 loop-directed antibody, while changes in the V1/V2 loops conferred partial resistance to this antibody. The epitopes of the neutralizing antibodies were not disrupted by the resistance-associated changes. These results indicate that in vivo selection occurs for HIV-1 envelope glycoproteins with variable loop conformations that restrict the access of antibodies to immunogenic neutralization epitopes.


Subject(s)
Antibodies, Viral/immunology , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Simian Immunodeficiency Virus/immunology , Animals , Antibody Specificity , Antigens, Viral/immunology , Epitopes/immunology , Humans
3.
J Virol ; 73(7): 5373-80, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10364284

ABSTRACT

A soluble form of the CD4 receptor (sCD4) can either enhance or inhibit the infection of cells by simian immunodeficiency virus (SIV) and human immunodeficiency virus. We investigated the basis for these varying effects by studying the entry of three SIV isolates into CD4-positive and CD4-negative cells expressing different chemokine receptors. Infection of CD4-negative cells depended upon the viral envelope glycoproteins and upon the chemokine receptor, with CCR5 and gpr15 being more efficient than STRL33. Likewise, enhancement of infection by sCD4 was observed when CCR5- and gpr15-expressing target cells were used but not when those expressing STRL33 were used. The sCD4-mediated enhancement of virus infection of CD4-negative, CCR5-positive cells was related to the sCD4-induced increase in binding of the viral gp120 envelope glycoprotein to CCR5. Inhibitory effects of sCD4 could largely be explained by competition for virus attachment to cellular CD4 rather than other detrimental effects on virus infectivity (e.g., disruption of the envelope glycoprotein spike). Consistent with this, the sCD4-activated SIV envelope glycoprotein intermediate on the virus was long-lived. Thus, the net effect of sCD4 on SIV infectivity appears to depend upon the degree of enhancement of chemokine receptor binding and upon the efficiency of competition for cellular CD4.


Subject(s)
CD4 Antigens/metabolism , CD4-Positive T-Lymphocytes/virology , Membrane Glycoproteins , Simian Immunodeficiency Virus/physiology , Viral Envelope Proteins , Animals , HIV Envelope Protein gp120/metabolism , HeLa Cells , Humans , Macaca mulatta , Simian Immunodeficiency Virus/isolation & purification , Solubility
4.
Virology ; 256(1): 15-21, 1999 Mar 30.
Article in English | MEDLINE | ID: mdl-10087222

ABSTRACT

To determine the role of viral burden in simian-human immunodeficiency virus (SHIV)-induced disease, cellular provirus and plasma viral RNA levels were measured after inoculation of rhesus monkeys with four different SHIVs. These SHIVs included SHIV-HXBc2 and SHIV-89.6, constructed with env, tat, rev, and vpu derived from either cell line-passaged or primary patient isolates of human immunodeficiency virus type 1; the viral quasispecies SHIV-89.6P derived after in vivo passage of SHIV-89.6; and a molecular clone, SHIV-KB9, derived from SHIV-89.6P. SHIV-HXBc2 and SHIV-89.6 are nonpathogenic in rhesus monkeys; SHIV-89.6P and SHIV-KB9 cause rapid CD4(+) T cell depletion and an immunodeficiency syndrome. Relative SHIV provirus levels were highest during primary infection in monkeys infected with SHIV-89.6P, the virus that caused the most rapid and dramatic CD4(+) T cell depletion. However, by 10 weeks postinoculation, provirus levels were similar in monkeys infected with the pathogenic and nonpathogenic chimeric viruses. The virus infections that resulted in the highest peak and chronic viral RNA levels were the pathogenic viruses SHIV-89.6P and SHIV-KB9. SHIV-89. 6P uniformly caused rapid and profound CD4(+) T cell depletion and immunodeficiency. Infection with the SHIV-KB9 resulted in very low CD4(+) T cell counts without seroconversion in some monkeys and a substantial but less profound CD4(+) T cell depletion and rapid seroconversion in others. Surprisingly, the level of plasma viremia did not differ between SHIV-KB9-infected animals exhibiting these contrasting outcomes, suggesting that host factors may play an important role in AIDS virus pathogenesis.


Subject(s)
Acquired Immunodeficiency Syndrome/physiopathology , HIV-2/pathogenicity , RNA, Viral/blood , Reassortant Viruses/pathogenicity , Simian Acquired Immunodeficiency Syndrome/physiopathology , Simian Immunodeficiency Virus/pathogenicity , Viral Load , Acquired Immunodeficiency Syndrome/blood , Acquired Immunodeficiency Syndrome/immunology , Animals , Antibodies, Viral/blood , CD4 Lymphocyte Count , Cell Line , Disease Progression , Genes, Viral , HIV Antibodies/blood , HIV-2/genetics , HIV-2/isolation & purification , Humans , Macaca mulatta , Proviruses/isolation & purification , Reassortant Viruses/genetics , Reassortant Viruses/isolation & purification , Simian Acquired Immunodeficiency Syndrome/blood , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/isolation & purification
5.
J Virol ; 73(2): 976-84, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9882298

ABSTRACT

In vivo passage of a poorly replicating, nonpathogenic simian-human immunodeficiency virus (SHIV-HXBc2) generated an efficiently replicating virus, KU-1, that caused rapid CD4(+) T-lymphocyte depletion and AIDS-like illness in monkeys (S. V. Joag, Z. Li, L. Foresman, E. B. Stephens, L.-J. Zhao, I. Adany, D. M. Pinson, H. M. McClure, and O. Narayan, J. Virol. 70:3189-3197, 1996). The env gene of the KU-1 virus was used to create a molecularly cloned virus, SHIV-HXBc2P 3.2, that differed from a nonpathogenic SHIV-HXBc2 virus in only 12 envelope glycoprotein residues. SHIV-HXBc2P 3.2 replicated efficiently and caused rapid and persistent CD4(+) T-lymphocyte depletion in inoculated rhesus macaques. Compared with the envelope glycoproteins of the parental SHIV-HXBc2, the SHIV-HXBc2P 3.2 envelope glycoproteins supported more efficient infection of rhesus monkey peripheral blood mononuclear cells. Both the parental SHIV-HXBc2 and the pathogenic SHIV-HXBc2P 3.2 used CXCR4 but none of the other seven transmembrane segment receptors tested as a second receptor. Compared with the parental virus, viruses with the SHIV-HXBc2P 3.2 envelope glycoproteins were more resistant to neutralization by soluble CD4 and antibodies. Thus, changes in the envelope glycoproteins account for the ability of the passaged virus to deplete CD4(+) T lymphocytes rapidly and specify increased replicative capacity and resistance to neutralization.


Subject(s)
Glycoproteins/physiology , HIV-1/pathogenicity , Reassortant Viruses/pathogenicity , Simian Immunodeficiency Virus/pathogenicity , Viral Envelope Proteins/physiology , Amino Acid Sequence , Animals , Base Sequence , COS Cells , Cell Line, Transformed , DNA, Viral , Glycoproteins/genetics , HIV-1/genetics , HIV-1/immunology , HIV-1/physiology , HeLa Cells , Humans , Leukocytes, Mononuclear/virology , Macaca mulatta , Macrophage Activation , Macrophages/virology , Molecular Sequence Data , Neutralization Tests , Reassortant Viruses/genetics , Reassortant Viruses/immunology , Serial Passage , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/physiology , Viral Envelope Proteins/genetics , Virus Replication
6.
J Exp Med ; 188(6): 1159-71, 1998 Sep 21.
Article in English | MEDLINE | ID: mdl-9743534

ABSTRACT

CD4+ T lymphocyte depletion in human immunodeficiency virus type 1 (HIV-1)-infected humans underlies the development of acquired immune deficiency syndrome. Using a model in which rhesus macaques were infected with chimeric simian-human immunodeficiency viruses (SHIVs), we show that both the level of viremia and the structure of the HIV-1 envelope glycoprotein ectodomains individually contributed to the efficiency with which CD4(+) T lymphocytes were depleted. The envelope glycoproteins of recombinant SHIVs that efficiently caused loss of CD4(+) T lymphocytes exhibited increased chemokine receptor binding and membrane-fusing capacity compared with those of less pathogenic viruses. These studies identify the HIV-1 envelope glycoprotein ectodomains as determinants of CD4(+) T lymphocyte loss in vivo and provide a foundation for studying pathogenic mechanisms.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , HIV-1/immunology , Lymphocyte Depletion , Simian Acquired Immunodeficiency Syndrome/immunology , Viral Envelope Proteins/physiology , Animals , Antiviral Agents/immunology , CD4-Positive T-Lymphocytes/virology , Chimera/immunology , Giant Cells/virology , HIV-1/genetics , HIV-1/pathogenicity , Humans , Lymph Nodes/virology , Lymphocyte Count , Macaca mulatta , Neutralization Tests , Protein Structure, Tertiary , Simian Acquired Immunodeficiency Syndrome/genetics , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/immunology , Simian Immunodeficiency Virus/pathogenicity , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics , Virus Replication/genetics , Virus Replication/immunology
7.
J Virol ; 72(10): 8437-45, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9733899

ABSTRACT

We characterized human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein epitopes recognized by neutralizing antibodies from monkeys recently infected by molecularly cloned simian-human immunodeficiency virus (SHIV) variants. The early neutralizing antibody response in each infected animal was directed mainly against a single epitope. This primary neutralizing epitope, however, differed among individual monkeys infected by identical viruses. Two such neutralization epitopes were determined by sequences in the V2 and V3 loops of the gp120 envelope glycoprotein, while a third neutralization epitope, apparently discontinuous, was determined by both V2 and V3 sequences. These results indicate that the early neutralizing antibody response in SHIV-infected monkeys is monospecific and directed against epitopes composed of the gp120 V2 and V3 variable loops.


Subject(s)
Epitopes/immunology , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Simian Immunodeficiency Virus/immunology , Animals , HIV Infections/immunology , HIV Infections/virology , Macaca mulatta , Neutralization Tests
8.
J Virol ; 71(11): 8582-91, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9343216

ABSTRACT

It has been suggested that naive immunoglobulins encoded by the V(H)3 gene family interact aberrantly with human immunodeficiency virus type 1 (HIV-1) gp120 via a superantigenic epitope, causing initial expansion and eventual depletion of V(H)3-expressing B cells. However, this possibility has not been prospectively assessed during an AIDS virus infection. We determined V(H) family usage in rhesus monkeys during primary infection with chimeric viruses expressing HIV-1 envelopes on a simian immunodeficiency virus (SIVmac) backbone (SHIVs). Four SHIVs with different envelopes and pathogenicities were studied. V(H) family usage was prospectively assessed in peripheral blood mononuclear cells and lymph node cells of these monkeys by a semiquantitative PCR technique. In the first months following SHIV infection, a period of intense viral antigenemia, representation of various V(H) families increased or decreased for individual monkeys, but no single V(H) family was consistently altered. In particular, the average representation of V(H)3-bearing B lymphocytes did not change. This observation suggests that the envelope glycoprotein of HIV-1 does not selectively expand or deplete the V(H)3 repertoire of primate B cells during acute AIDS virus infection, contrary to predictions of the gp120 superantigen hypothesis.


Subject(s)
Gene Rearrangement, B-Lymphocyte, Heavy Chain , HIV Antibodies/genetics , HIV Envelope Protein gp120/immunology , HIV Infections/immunology , HIV-1/immunology , Immunoglobulin Variable Region/genetics , Reassortant Viruses/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Animals , B-Lymphocytes/cytology , DNA, Complementary/genetics , HIV Antigens/immunology , HIV-1/pathogenicity , Lymph Nodes/cytology , Lymphocyte Count , Macaca mulatta , Reassortant Viruses/pathogenicity , Simian Immunodeficiency Virus/pathogenicity
9.
J Virol ; 71(6): 4218-25, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9151808

ABSTRACT

In vivo passage of a chimeric simian-human immunodeficiency virus (SHIV-89.6) expressing the human immunodeficiency virus type 1 (HIV-1) tat, rev, vpu, and env genes generated pathogenic viruses (SHIV-89.6P) inducing rapid CD4+ lymphocyte depletion and AIDS-like illness in rhesus monkeys (K. Reimann, J. T. Li, R. Veazey, M. Halloran, I.-W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin, J. Virol. 70:6922-6928, 1996). To characterize the molecular changes responsible for this increase in virulence, infectious proviral clones of SHIV-89.6P isolates were derived. Viruses generated from some of these clones caused a rapid and profound decline of CD4+ lymphocytes in a high percentage of inoculated monkeys. Nucleotide changes potentially responsible for the increased virulence of SHIV-89.6P were limited to the env, tat, or long terminal repeat sequences, with most of the observed changes in env. Nucleotide changes in env altered 12 amino acids in the gp120 and gp41 exterior domains, and a 140-bp deletion in env resulted in the substitution of the carboxyl terminus of the SIVmac gp41 glycoprotein for that of the HIV-1 gp41 glycoprotein. The availability of pathogenic proviral clones should facilitate dissection of the molecular determinants of SHIV-89.6P virulence.


Subject(s)
CD4-Positive T-Lymphocytes/microbiology , HIV-1/genetics , Simian Immunodeficiency Virus/genetics , Animals , Base Sequence , CD4 Lymphocyte Count , Chimera , Cloning, Molecular , Genes, Viral , HIV-1/pathogenicity , Lymphocyte Depletion , Macaca mulatta , Molecular Sequence Data , Mutation , Proviruses/genetics , Proviruses/pathogenicity , Sequence Deletion , Simian Immunodeficiency Virus/pathogenicity , Viral Structural Proteins/genetics
10.
J Virol ; 70(10): 6922-8, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8794335

ABSTRACT

The utility of the simian immunodeficiency virus of macaques (SIVmac) model of AIDS has been limited by the genetic divergence of the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and the SIVs. To develop a better AIDS animal model, we have been exploring the infection of rhesus monkeys with chimeric simian/human immunodeficiency viruses (SHIVs) composed of SIVmac239 expressing HIV-1 env and the associated auxiliary HIV-1 genes tat, vpu, and rev. SHIV-89.6, constructed with the HIV-1 env of a cytopathic, macrophage-tropic clone of a patient isolate of HIV-1 (89.6), was previously shown to replicate to a high degree in monkeys during primary infection. However, pathogenic consequences of chronic infection were not evident. We now show that after two serial in vivo passages by intravenous blood inoculation of naive rhesus monkeys, this SHIV (SHIV-89.6P) induced CD4 lymphopenia and an AIDS-like disease with wasting and opportunistic infections. Genetic and serologic evaluation indicated that the reisolated SHIV-89.6P expressed envelope glycoproteins that resembled those of HIV-1. When inoculated into naive rhesus monkeys, SHIV-89.6P caused persistent infection and CD4 lymphopenia. This chimeric virus expressing patient isolate HIV-1 envelope glycoproteins will be valuable as a challenge virus for evaluating HIV-1 envelope-based vaccines and for exploring the genetic determinants of HIV-1 pathogenicity.


Subject(s)
Acquired Immunodeficiency Syndrome/virology , HIV Envelope Protein gp120/genetics , HIV-1/genetics , Reassortant Viruses/pathogenicity , Simian Immunodeficiency Virus/genetics , Acquired Immunodeficiency Syndrome/pathology , Amino Acid Sequence , Animals , HIV Envelope Protein gp120/biosynthesis , Humans , Macaca mulatta , Molecular Sequence Data , Reassortant Viruses/genetics , Virulence/genetics
11.
J Virol ; 70(10): 7143-52, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8794361

ABSTRACT

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin (NB-DNJ) is an inhibitor of human immunodeficiency virus (HIV) replication and HIV-induced syncytium formation in vitro. Although NB-DNJ appears to inhibit HIV entry at the level of post-CD4 binding (P.B. Fischer, M. Collin, G.B. Karlsson, W. James, T.D. Butters, S.J. Davis, S. Gordon, R.A. Dwek, and F.M. Platt, J. Virol. 69:5791-5797, 1995), the exact mechanism of action remains to be established. In this study we have examined the effect of NB-DNJ on the structure of recombinant gp120 (rgpl20), expressed in CHO cells, by using a panel of 40 monoclonal antibodies. The levels of binding of antibodies to rgp120 produced in the presence [rgpl20(+)] and absence [rgpl20(-)] of NB-DNJ were compared by enzyme-linked immunosorbent assay and surface plasmon resonance (BIAcore; Pharmacia). The results showed an increase in the binding to rgp120(+) of antibodies directed against the C1 and C2 regions and a decrease in the binding of antibodies directed against the V1/V2 loops compared with antibody binding to rgpl20(-). A decrease in the binding to rgpl20(+) of antibodies directed against discontinuous epitopes was also observed. No differences were seen in the binding of antibodies directed against the crown of the V3 loop and the C4 region of gp120. Treatment of rgpl20 with alpha-glucosidases I and II had no effect on the differential binding observed, whereas treatment with sialidase abolished the differences seen in the binding of antibodies directed against the C1 and C2 regions of gp120. In addition to these findings, rgpl20(+) showed increased sensitivity to proteases released by CHO cells during expression, as well as to exogenous thrombin. Taken together, the data presented in this paper suggest that production of gp120 in the presence of NB-DNJ affects the conformation of the Vl/V2 loops of gpl20, as well as the overall charge of the C1 and C2 regions. These effects may play a role in the previously described NB-DNJ-mediated inhibition of HIV entry at the level of post-CD4 binding.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Antiviral Agents/pharmacology , HIV Antibodies/immunology , HIV Envelope Protein gp120/immunology , HIV Infections , HIV-1/drug effects , Virus Replication/drug effects , 1-Deoxynojirimycin/pharmacology , Animals , CHO Cells , Cricetinae , Epitopes/immunology , HIV Envelope Protein gp120/metabolism , HIV-1/physiology , Humans , Protein Conformation
12.
J Virol ; 70(10): 7153-60, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8794362

ABSTRACT

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin (NB-DNJ) is an inhibitor of human immunodeficiency virus (HIV) replication and HIV-induced syncytium formation in vitro. Although an NB-DNJ-mediated change in viral envelope N-glycan composition inhibits HIV entry at the level of post-CD4 binding, the exact mechanism of inhibition remains to be established. In this study we have examined the effects of NB-DNJ on virion envelope composition and CD4-induced gp120 shedding and gp41 exposure. Virion composition analysis revealed an NB-DNJ-mediated reduction of 15% in overall virion envelope glycoprotein content and a reduction of 26% in the proteolytic maturation of virion gp160. Taken together, these two effects resulted in a reduction of approximately 40% in virion gp120 content. CD4-induced shedding of gp120 from the surfaces of envelope-transfected Cos cells was undetectable when gp120 was expressed in the presence of NB-DNJ. Similarly, the shedding of virion-associated gp120 was reduced 7.4-fold. CD4-induced exposure of cryptic gp41 epitopes on the surfaces of HIV-expressing ACH-2 cells was also greatly impaired, and the exposure of virion-associated gp41 epitopes was reduced 4.0-fold. Finally, CD4-induced increases in the binding of antibodies to the V3 loop of ACH-2-cell-expressed envelope glycoproteins were reduced 25-fold when the glycoproteins were expressed in the presence of NB-DNJ. These results suggest that the NB-DNJ-mediated retention of glycosylated N-glycans inhibits HIV entry by a combined effect of a reduction in virion gp120 content and a qualitative defect within the remaining gp120, preventing it from undergoing conformational changes after CD4 binding.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Antiviral Agents/pharmacology , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/metabolism , HIV Infections/virology , HIV-1/physiology , Virus Replication/drug effects , 1-Deoxynojirimycin/pharmacology , Animals , CHO Cells , Cricetinae , HIV Envelope Protein gp120/drug effects , HIV Envelope Protein gp41/drug effects , HIV-1/drug effects , Humans
13.
J Virol ; 70(9): 6136-42, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8709238

ABSTRACT

Previous observations that the gp120 envelope glycoprotein contents of some primary, clade B human immunodeficiency virus type 1 (HIV-1) isolates were higher than those of laboratory-passaged HIV-1 isolates suggested the hypothesis that increased envelope glycoprotein spike density or stability contributes to the relative neutralization resistance of the primary viruses. To test this, the structural, replicative, and neutralization properties of a panel of recombinant viruses with HIV-1 envelope glycoproteins from divergent clades were examined in an env complementation assay. In this system, although the spike density and stability of envelope glycoproteins from primary HIV-1 isolates were not greater than those from a laboratory-adapted isolate, relative resistance to neutralizing antibodies and soluble CD4 was observed for the viruses with primary envelope glycoproteins. Thus, neither high envelope glycoprotein spike density nor stability is necessary for the relative neutralization resistance of primary HIV-1 viruses.


Subject(s)
Gene Products, env/biosynthesis , Genes, env , HIV Antibodies , HIV Envelope Protein gp120/biosynthesis , HIV Envelope Protein gp120/immunology , HIV-1/physiology , Virus Replication , Antigens, CD/biosynthesis , CD4 Antigens/biosynthesis , Cell Line , Chloramphenicol O-Acetyltransferase/biosynthesis , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/biosynthesis , HIV-1/immunology , HIV-1/isolation & purification , HeLa Cells , Humans , Kinetics , Neutralization Tests , Recombinant Fusion Proteins/biosynthesis , T-Lymphocytes , Transfection , Virion/immunology , Virion/physiology
14.
J Virol ; 69(9): 5791-7, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7543588

ABSTRACT

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin (NB-DNJ) is a potent inhibitor of human immunodeficiency virus (HIV) replication and syncytium formation in vitro. However, the exact mechanism of action of NB-DNJ remains to be determined. In this study we have examined the impairment of HIV infectivity mediated by NB-DNJ. By two independent HIV entry assays [PCR-based HIV entry assay and entry of Cocal(HIV) pseudotypes], the reduction in infectivity was found to be due to an impairment of viral entry. No effect of NB-DNJ treatment was seen on the kinetics of the interaction between gp120 and CD4 (surface plasmon resonance; BIAcore) or on the binding of virus particles to H9 cells (using radiolabeled virions). We therefore conclude that a major mechanism of action of NB-DNJ as an inhibitor of HIV replication is the impairment of viral entry at the level of post-CD4 binding, due to an effect on viral envelope components.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Antiviral Agents/pharmacology , CD4 Antigens/physiology , Glycoside Hydrolase Inhibitors , HIV-1/physiology , HIV-1/pathogenicity , Virus Replication/drug effects , 1-Deoxynojirimycin/pharmacology , Cell Line , HIV Envelope Protein gp120/metabolism , HIV Reverse Transcriptase , HIV-1/drug effects , Humans , Kinetics , RNA-Directed DNA Polymerase/analysis , Receptors, Virus/physiology , Time Factors , Virion/drug effects , Virion/pathogenicity , Virion/physiology
15.
J Biol Chem ; 269(43): 27108-14, 1994 Oct 28.
Article in English | MEDLINE | ID: mdl-7929454

ABSTRACT

We have previously reported that the imino sugar N-butyldeoxynojirimycin (NB-DNJ) inhibits glycolipid biosynthesis, in addition to its known activity as an inhibitor of the N-linked oligosaccharide processing enzyme alpha-glucosidase I. In an attempt to dissociate these two activities and identify an inhibitor which was more selective for the glycolipid biosynthetic pathway, several imino sugars have been N-alkylated and tested for inhibitory activity. The galactose analogue N-butyldeoxygalactonojirimycin (NB-DGJ) was found to be a potent inhibitor of glycolipid biosynthesis but in contrast to NB-DNJ had no effect on the maturation of N-linked oligosaccharides or on lysosomal glucocerebrosidase. The effect of increasing N-alkyl chain length on glycolipid inhibition was investigated. Nonalkylated DGJ, the N-methyl and N-ethyl derivatives, were noninhibitory. However, N-propylation resulted in partial inhibition while the N-butyl and N-hexyl derivatives resulted in maximal inhibition. Increasing alkyl chain length also resulted in increased potency of glucosyltransferase inhibition. In an in vitro Gaucher's disease model NB-DGJ was as effective as NB-DNJ in preventing glycolipid storage and may represent a more selective potential therapeutic agent than NB-DNJ for the management of this and other glycosphingolipidoses.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Glycolipids/biosynthesis , Oligosaccharides/biosynthesis , 1-Deoxynojirimycin/pharmacology , Animals , Cells, Cultured , Disease Models, Animal , Gaucher Disease/metabolism , Glucosylceramidase/drug effects , Glucosyltransferases/antagonists & inhibitors , Humans , Mice , Structure-Activity Relationship , alpha-Glucosidases/drug effects
16.
J Biol Chem ; 268(1): 570-6, 1993 Jan 05.
Article in English | MEDLINE | ID: mdl-8416962

ABSTRACT

The imino sugar N-butyldeoxynojirimycin (NB-DNJ) exhibits anti-HIV activity in vitro and inhibits the purified glycoprocessing enzyme alpha 1,2-glucosidase I. It has been speculated that the anti-viral activity of this compound may result from inhibition of HIV envelope glycoprotein processing. However, structural evidence that glucosidase inhibition takes place in intact cells at the anti-viral concentration (0.5 mM) is lacking. In this study, N-linked glycosylation of recombinant gp120 expressed in Chinese hamster ovary cells cultured in the presence or absence of NB-DNJ has been characterized. Immunoprecipitation, in conjunction with endoglycosidase H (endo H) digestion and SDS-polyacrylamide gel electrophoresis analysis, revealed that the glycosylation of gp120 was profoundly altered in the presence of NB-DNJ. The majority of the gp120 oligosaccharides from untreated cells were resistant to endo H. However, nearly complete endo H sensitivity was observed following treatment with 0.5 mM NB-DNJ indicating that gp120 expressed in treated cells carries immature, high mannose type oligosaccharides. In addition, using metabolic labeling with [3H]mannose, gel filtration chromatography, and digestion with highly purified glucosidases I and II, we provide the first definitive evidence that glucosidase I inhibition occurs at the anti-viral concentration of NB-DNJ. These data indicate that glucosidase inhibition is a candidate mechanism for the anti-viral activity of this compound.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Antiviral Agents/pharmacology , HIV Envelope Protein gp120/metabolism , HIV-1/metabolism , Mannose/metabolism , 1-Deoxynojirimycin/pharmacology , Animals , CHO Cells , Carbon Radioisotopes , Chromatography, Gel , Cricetinae , Glycosylation , HIV Envelope Protein gp120/biosynthesis , HIV Envelope Protein gp120/isolation & purification , HIV-1/drug effects , Hexosaminidases , Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase , Methionine/metabolism , Oligosaccharides/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Sulfur Radioisotopes , Transfection , Tritium
17.
Eur J Biochem ; 208(1): 187-93, 1992 Aug 15.
Article in English | MEDLINE | ID: mdl-1387360

ABSTRACT

The imino sugar, N-butyldeoxynojirimycin, is an inhibitor of the glycoprotein-processing enzyme glucosidase I and exhibits anti-(human immunodeficiency virus) activity in vitro. We have investigated the effect(s) of this compound on cell-surface glycoproteins by flow cytometry. We observed selective modulation of the transferrin receptor in response to treatment with 0.5 mM N-butyldeoxynojirimycin resulting in reduced cell-surface transferrin-receptor expression. The receptor modulation was dose dependent, resulted in reduced 59Fe uptake by treated cells and was fully reversible within 24 h of culture in the absence of the compound. Pulse/chase analysis in conjunction with endoglycosidase-H digestion demonstrated that transferrin-receptor glycosylation was altered following N-butyldeoxynojirimycin treatment, which is compatible with glucosidase inhibition. In addition, modulation of transferrin receptor in response to N-butyldeoxynojirimycin was not confined to a single cell line, but was also observed with certain human lymphoid and myeloid cell lines. Mechanism(s) of action of the imino sugar resulting in reduced cell-surface transferrin-receptor expression are discussed.


Subject(s)
Antiviral Agents/pharmacology , Glucosamine/analogs & derivatives , Receptors, Transferrin/drug effects , 1-Deoxynojirimycin , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , Glucosamine/pharmacology , Glycoside Hydrolases/antagonists & inhibitors , HIV/drug effects , Humans , Kinetics , Receptors, Transferrin/biosynthesis , Receptors, Transferrin/metabolism , Transferrin/metabolism
18.
Anal Biochem ; 199(2): 219-22, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1812788

ABSTRACT

A method is described for the use of magnetic beads as a solid phase for the immunoprecipitation of labeled proteins. The anti-human transferrin receptor monoclonal antibody OKT-9 has been coupled to sheep anti-mouse IgG1-coated magnetic beads using the crosslinking agent dimethyl pimelimidate. The transferrin receptor is readily detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography following immunoprecipitation from 35S-labeled cell lysates. When compared with precipitations using OKT-9 coupled to protein G Sepharose the magnetic beads result in fewer nonspecific bands. The protocol described is generally applicable to the identification of labeled proteins. In addition, because magnetic beads are amenable to covalent crosslinking procedures they can be used for the purification of proteins from complex mixtures. Covalently crosslinked OKT-9 sheep anti-mouse IgG1-coated magnetic beads have been used to affinity purify unlabeled transferrin receptor from cell lysates giving comparable purity and yield to transferrin Sepharose isolated transferrin receptor. The major advantages offered by magnetic beads compared to conventional affinity matrices are low nonspecific binding and the rapidity with which the purification can be performed.


Subject(s)
Chromatography, Affinity/methods , Precipitin Tests/methods , Receptors, Transferrin/analysis , Antibodies, Monoclonal , Cell Line , Humans , Immunoglobulin G/chemistry , Magnetics , Nerve Tissue Proteins/chemistry , Receptors, Transferrin/immunology , Receptors, Transferrin/isolation & purification , Sepharose/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...